Tenax Therapeutics Faces Securities Class Action Lawsuit
A law firm has filed a class action against Tenax Therapeutics over alleged investor losses tied to securities purchased between late 2023 and mid-2026.
A New York-based law firm has announced a securities class action lawsuit against Tenax Therapeutics, Inc., traded on the Nasdaq under the ticker TENX, targeting alleged damages suffered by investors who purchased shares during a roughly three-year window.
Bronstein Gewirtz & Grossman, LLC filed the suit on behalf of investors who bought TENX securities between November 13, 2023, and August 7, 2026. The firm is encouraging affected shareholders to come forward ahead of a lead plaintiff deadline set for December 28, 2026.
Read more ChoiceOne Financial Posts $14.5M Net Income in Third Quarter 2026 →
Under federal securities law, investors who suffered losses during the defined class period may be eligible to seek recovery through the litigation. The lead plaintiff, typically the investor or group with the largest financial stake, is responsible for directing the lawsuit on behalf of the broader class.
Securities class actions of this type generally allege that a company or its executives made materially false or misleading statements that artificially affected the stock price, causing losses when corrective information emerged. The complaint targets damages accrued over the multi-year period in question, though the specific allegations underlying the case were not fully detailed in the announcement.
Investors with potential claims are advised to consult legal counsel before the December 2026 deadline to preserve their right to participate as lead plaintiff. Continue reading at Banking & Financial Services.
